Abstract
Macrophage migration inhibitory factor (MIF) is a pleiotropic immunoregulatory cytokine whose effects on arresting ‘random’ immune cell movement was already recognized decades ago. MIF is quasi-constitutively expressed by a variety of different cells and tissues, including immune cells such as T-cells and monocytes/macrophages, but also nonimmune cells like certain endocrine cells and cells lining interior body cavities or contacting the exterior environment, such as endothelial cells (ECs), or epithelial cells in kidney, gut and skin. Contrary to its historic name, MIF has a direct chemokine-like function and promotes ‘directed’ cell migration (i.e. chemotaxis) and plays a prominent role in inflammatory and atherogenic leukocyte recruitment. At the molecular level, these activities are based on a non-cognate interaction between MIF and the CXC chemokine receptors CXCR2 and CXCR4. Importantly, MIF also interacts with surface CD74, a type II transmembrane protein, inducing its phosphorylation and the recruitment of CD44, leading ultimately to ERK1/2 phosphorylation. Multiple studies have pointed to the utility of MIF as a biomarker for different diseases that have an inflammatory component; these include systemic infections and sepsis, cancer, autoimmune diseases as well as different metabolic disorders. In this Review, we highlight the suitability of MIF and CD74 as biomarkers for different disease applications.
Keywords: Biomarker, CD74, macrophage migration inhibitory factor (MIF), macrophage migration inhibitory factor receptor.
Mini-Reviews in Medicinal Chemistry
Title:MIF and CD74 - Suitability as Clinical Biomarkers
Volume: 14 Issue: 14
Author(s): Gerrit Grieb, Bong-Sung Kim, David Simons, Jurgen Bernhagen and Norbert Pallua
Affiliation:
Keywords: Biomarker, CD74, macrophage migration inhibitory factor (MIF), macrophage migration inhibitory factor receptor.
Abstract: Macrophage migration inhibitory factor (MIF) is a pleiotropic immunoregulatory cytokine whose effects on arresting ‘random’ immune cell movement was already recognized decades ago. MIF is quasi-constitutively expressed by a variety of different cells and tissues, including immune cells such as T-cells and monocytes/macrophages, but also nonimmune cells like certain endocrine cells and cells lining interior body cavities or contacting the exterior environment, such as endothelial cells (ECs), or epithelial cells in kidney, gut and skin. Contrary to its historic name, MIF has a direct chemokine-like function and promotes ‘directed’ cell migration (i.e. chemotaxis) and plays a prominent role in inflammatory and atherogenic leukocyte recruitment. At the molecular level, these activities are based on a non-cognate interaction between MIF and the CXC chemokine receptors CXCR2 and CXCR4. Importantly, MIF also interacts with surface CD74, a type II transmembrane protein, inducing its phosphorylation and the recruitment of CD44, leading ultimately to ERK1/2 phosphorylation. Multiple studies have pointed to the utility of MIF as a biomarker for different diseases that have an inflammatory component; these include systemic infections and sepsis, cancer, autoimmune diseases as well as different metabolic disorders. In this Review, we highlight the suitability of MIF and CD74 as biomarkers for different disease applications.
Export Options
About this article
Cite this article as:
Grieb Gerrit, Kim Bong-Sung, Simons David, Bernhagen Jurgen and Pallua Norbert, MIF and CD74 - Suitability as Clinical Biomarkers, Mini-Reviews in Medicinal Chemistry 2014; 14 (14) . https://dx.doi.org/10.2174/1389557515666150203143317
DOI https://dx.doi.org/10.2174/1389557515666150203143317 |
Print ISSN 1389-5575 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5607 |
Call for Papers in Thematic Issues
Bioprospecting of Natural Products as Sources of New Multitarget Therapies
According to the Convention on Biological Diversity, bioprospecting is the exploration of biodiversity and indigenous knowledge to develop commercially valuable products for pharmaceutical and other applications. Bioprospecting involves searching for useful organic compounds in plants, fungi, marine organisms, and microorganisms. Natural products traditionally constituted the primary source of more than ...read more
Computational Frontiers in Medicinal Chemistry
The thematic issue "Computational Frontiers in Medicinal Chemistry" provides a robust platform for delving into state-of-the-art computational methodologies and technologies that significantly propel advancements in medicinal chemistry. This edition seeks to amalgamate top-tier reviews spotlighting the latest trends and breakthroughs in the fusion of computational approaches, including artificial intelligence (AI) ...read more
Natural Products and Dietary Supplements in Alleviation of Metabolic, Cardiovascular, and Neurological Disorders
Metabolic disorders like diabetes, obesity, inflammation, oxidative stress, cancer etc, cardiovascular disorders like angina, myocardial infarction, congestive heart failure etc as well as neurological disorders like Alzheimer?s, Parkinson?s, Epilepsy, Depression, etc are the global burden. They covered the major segment of the diseases and disorders from which the human community ...read more
Natural Products in Drug Discovery
Natural products have always been one of the important ways of drug discovery due to their novel skeleton and diverse functional group characteristics. According to statistics, between 1981 and 2019, the FDA approved a total of 1,394 small molecule drugs for marketing, of which 930 marketed drugs originated from the ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Lessons from the Drug Discovery of Lapatinib, a Dual ErbB1/2 Tyrosine Kinase Inhibitor
Current Topics in Medicinal Chemistry Overcoming Resistance of Glioblastoma to Conventional Cytotoxic Therapies by the Addition of PARP Inhibitors
Anti-Cancer Agents in Medicinal Chemistry Histone Deacetylase Inhibitors in Cancer Treatment: A Review of the Clinical Toxicity and the Modulation of Gene Expression in Cancer Cells
Current Pharmaceutical Biotechnology Identification of Critical MicroRNA Gene Targets in Cervical Cancer Using Network Properties
MicroRNA Fluorine-18 Labeled Amino Acids for Oncologic Imaging with Positron Emission Tomography
Current Topics in Medicinal Chemistry Light Alcohol Drinking and the Risk of Cancer Development: A Controversial Relationship
Reviews on Recent Clinical Trials Herbal Phytochemicals as Immunomodulators
Current Immunology Reviews (Discontinued) Expression and Function of Kruppel Like-Factors (KLF) in Carcinogenesis
Current Genomics ADAM10 as a Therapeutic Target for Cancer and Inflammation
Current Pharmaceutical Design Role of Class II Nuclear Receptors in Liver Carcinogenesis
Anti-Cancer Agents in Medicinal Chemistry Identification of Drug Candidates for Breast Cancer Therapy Through Scaffold Repurposing: A Brief Review
Current Drug Research Reviews The Therapeutic Potential of Targeting Autophagy in the Treatment of Cancer
Current Cancer Drug Targets Recent Advances in Azo Dye Degrading Enzyme Research
Current Protein & Peptide Science Alternative Splicing, DNA Damage and Modulating Drugs in Radiation Therapy for Cancer
Anti-Cancer Agents in Medicinal Chemistry Preface
Anti-Cancer Agents in Medicinal Chemistry Natural Products Targeting Autophagy via the PI3K/Akt/mTOR Pathway as Anticancer Agents
Anti-Cancer Agents in Medicinal Chemistry NBN Polymorphysms and Cancer Susceptibility: A Systematic Review
Current Genomics Medical Treatment of Overactive Bladder: An Overview
Current Clinical Pharmacology Processed Foods, Dysbiosis, Systemic Inflammation, and Poor Health
Current Nutrition & Food Science Oxidative Stress and Mitochondrial Dysfunction in Type 2 Diabetes
Current Pharmaceutical Design